Jonathan McNeill - 10 Jul 2021 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Role
Senior Vice President of Business Development
Signature
/s/ Richard Scalzo, Attorney-in-Fact
Issuer symbol
DYN
Transactions as of
10 Jul 2021
Transactions value $
$0
Form type
4
Filing time
13 Jul 2021, 16:22:39 UTC
Next filing
22 Sep 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DYN Stock Option (right to buy) Award $0 +25,000 $0 25,000 10 Jul 2021 Common Stock 25,000 $21.01 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on July 10, 2021. The shares underlying the option are scheduled to vest over four years in equal quarterly installments from July 1, 2021.

Remarks:

Senior Vice President of Business Development